FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma
Abstract We have reported that the FAN score, which consists of the fibrosis-4 (Fib-4) index, albumin–bilirubin (ALBI) score, and neutrophil–lymphocyte ratio (NLR), is a prognostic marker for patients receiving pembrolizumab for mUC. However, it remains unclear whether the FAN score is a prognostic...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-02-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-86212-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862262590341120 |
|---|---|
| author | Yu Ishizuya Atsunari Kawashima Yuki Horibe Akinaru Yamamoto Masaru Tani Akihiro Yoshimura Liu Yutong Sassi Nesrine Toshiki Oka Yohei Okuda Toshihiro Uemura Gaku Yamamichi Takuji Hayashi Yoshiyuki Yamamoto Taigo Kato Koji Hatano Norio Nonomura |
| author_facet | Yu Ishizuya Atsunari Kawashima Yuki Horibe Akinaru Yamamoto Masaru Tani Akihiro Yoshimura Liu Yutong Sassi Nesrine Toshiki Oka Yohei Okuda Toshihiro Uemura Gaku Yamamichi Takuji Hayashi Yoshiyuki Yamamoto Taigo Kato Koji Hatano Norio Nonomura |
| author_sort | Yu Ishizuya |
| collection | DOAJ |
| description | Abstract We have reported that the FAN score, which consists of the fibrosis-4 (Fib-4) index, albumin–bilirubin (ALBI) score, and neutrophil–lymphocyte ratio (NLR), is a prognostic marker for patients receiving pembrolizumab for mUC. However, it remains unclear whether the FAN score is a prognostic factor for platinum-based first-line chemotherapy. We included 126 patients with mUC who received platinum-based first-line chemotherapy. The median PFS and overall survival (OS) were 6.3 months (95% confidence interval [CI] 4.5–8.0) and 14.0 months (95% CI 11.1–16.9), respectively. Multivariable analysis showed that Fib-4 index (HR 3.85, 95% CI 1.09–13.58, p = 0.036), ALBI score (HR 1.53, 95% CI 1.01–2.31, p = 0.045), and NLR (HR 1.76, 95% CI 1.14–2.71, p = 0.010) were independently associated with PFS. The FAN score was also associated with PFS (HR 2.56, 95% CI 1.62–4.05, p < 0.001). The median PFS for patients with low FAN score (≤ 1) and those with high FAN score (≥ 2) were 7.8 (95% CI 5.0–9.0) months and 3.0 (95% CI 1.6–5.8) months, respectively. In conclusion, the FAN score is a prognostic factor for mUC patients who are treated with platinum-based first-line chemotherapy. |
| format | Article |
| id | doaj-art-efb4cfab9a7849bab8c3bd13626c88fe |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-efb4cfab9a7849bab8c3bd13626c88fe2025-02-09T12:37:12ZengNature PortfolioScientific Reports2045-23222025-02-0115111210.1038/s41598-025-86212-7FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinomaYu Ishizuya0Atsunari Kawashima1Yuki Horibe2Akinaru Yamamoto3Masaru Tani4Akihiro Yoshimura5Liu Yutong6Sassi Nesrine7Toshiki Oka8Yohei Okuda9Toshihiro Uemura10Gaku Yamamichi11Takuji Hayashi12Yoshiyuki Yamamoto13Taigo Kato14Koji Hatano15Norio Nonomura16Department of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineDepartment of Urology, Osaka University Graduate School of MedicineAbstract We have reported that the FAN score, which consists of the fibrosis-4 (Fib-4) index, albumin–bilirubin (ALBI) score, and neutrophil–lymphocyte ratio (NLR), is a prognostic marker for patients receiving pembrolizumab for mUC. However, it remains unclear whether the FAN score is a prognostic factor for platinum-based first-line chemotherapy. We included 126 patients with mUC who received platinum-based first-line chemotherapy. The median PFS and overall survival (OS) were 6.3 months (95% confidence interval [CI] 4.5–8.0) and 14.0 months (95% CI 11.1–16.9), respectively. Multivariable analysis showed that Fib-4 index (HR 3.85, 95% CI 1.09–13.58, p = 0.036), ALBI score (HR 1.53, 95% CI 1.01–2.31, p = 0.045), and NLR (HR 1.76, 95% CI 1.14–2.71, p = 0.010) were independently associated with PFS. The FAN score was also associated with PFS (HR 2.56, 95% CI 1.62–4.05, p < 0.001). The median PFS for patients with low FAN score (≤ 1) and those with high FAN score (≥ 2) were 7.8 (95% CI 5.0–9.0) months and 3.0 (95% CI 1.6–5.8) months, respectively. In conclusion, the FAN score is a prognostic factor for mUC patients who are treated with platinum-based first-line chemotherapy.https://doi.org/10.1038/s41598-025-86212-7Urothelial carcinomaPlatinum-based chemotherapyFib-4 indexALBI scoreNLRPrognostic factor |
| spellingShingle | Yu Ishizuya Atsunari Kawashima Yuki Horibe Akinaru Yamamoto Masaru Tani Akihiro Yoshimura Liu Yutong Sassi Nesrine Toshiki Oka Yohei Okuda Toshihiro Uemura Gaku Yamamichi Takuji Hayashi Yoshiyuki Yamamoto Taigo Kato Koji Hatano Norio Nonomura FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma Scientific Reports Urothelial carcinoma Platinum-based chemotherapy Fib-4 index ALBI score NLR Prognostic factor |
| title | FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma |
| title_full | FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma |
| title_fullStr | FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma |
| title_full_unstemmed | FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma |
| title_short | FAN score predicts prognosis after platinum-based first-line chemotherapy in patients with metastatic urothelial carcinoma |
| title_sort | fan score predicts prognosis after platinum based first line chemotherapy in patients with metastatic urothelial carcinoma |
| topic | Urothelial carcinoma Platinum-based chemotherapy Fib-4 index ALBI score NLR Prognostic factor |
| url | https://doi.org/10.1038/s41598-025-86212-7 |
| work_keys_str_mv | AT yuishizuya fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT atsunarikawashima fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT yukihoribe fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT akinaruyamamoto fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT masarutani fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT akihiroyoshimura fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT liuyutong fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT sassinesrine fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT toshikioka fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT yoheiokuda fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT toshihirouemura fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT gakuyamamichi fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT takujihayashi fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT yoshiyukiyamamoto fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT taigokato fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT kojihatano fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma AT noriononomura fanscorepredictsprognosisafterplatinumbasedfirstlinechemotherapyinpatientswithmetastaticurothelialcarcinoma |